uniQure (Gene Therapy Portfolio Rights) Overview

  • Status

  • Acquired/​Merged

  • Latest Deal Type

  • Asset Purch.

  • Financing Rounds

  • 1

uniQure (Gene Therapy Portfolio Rights) General Information

Description

Global rights of gene therapy program for hemophilia B.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Acquirer
CSL Behring
Primary Office
  • Postbus 22506
  • 1100 DA Amsterdam
  • Netherlands

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

uniQure (Gene Therapy Portfolio Rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore uniQure (Gene Therapy Portfolio Rights)‘s full profile, request access.

Request a free trial

uniQure (Gene Therapy Portfolio Rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore uniQure (Gene Therapy Portfolio Rights)‘s full profile, request access.

Request a free trial